Regulatory writing for rare disease
Small N, single-arm trials, natural-history comparators, and a heavy load of post-marketing commitments. Asthra drafts with precision where every subject counts.
Rare-disease regulatory writing is unlike anything else in the industry. Sample sizes are small — sometimes in the single digits per stratum. Single-arm studies against historical or natural-history controls are common. Accelerated approval pathways, breakthrough designations, and orphan status shape the submission strategy from the first protocol. And the post-marketing commitments (PMCs and PMRs) often stretch beyond the initial approval in ways that dwarf the original trial. Asthra handles the drafting load so writers can focus on the small-N clinical nuance that actually moves the review.
Regulatory pressure points in rare disease
Where Asthra changes the shape of the work
Small N demands per-subject narrative
When a pivotal trial has 20 subjects in the treated arm, every case narrative matters. Asthra drafts per-subject safety narratives from the line-listings and the narrative conventions set in the protocol, with every claim sourced.
Natural-history comparators require careful framing
Single-arm studies compare against published natural history or patient-registry data. Asthra pulls from approved literature sources and registries, cites them by paper and passage, and keeps the comparison framing consistent across CSR and briefing documents.
Accelerated approval and post-marketing commitments
PMCs and PMRs tied to accelerated approval are long-lived commitments. Asthra maintains consistency between the original approval narrative and the later PMC/PMR updates, so the story does not drift across cycles.
Orphan drug and breakthrough designations
Designation-specific content (orphan designation requests, breakthrough therapy requests, PRIME applications) follows patterns that repeat across programs. Asthra uses the same closed-system retrieval to draft these as the CSR, so the source framing is consistent.
Patient-community and advocacy-informed development
Rare-disease programs often incorporate patient-community input into endpoint selection and trial design. That context belongs in the Introduction and Study Design sections of the CSR. Asthra will include it when the source protocol does, and will not invent it when it does not.
Documents Asthra drafts for this area
The regulated documents you produce most often
CSR (ICH E3)
Full CSR first draft with per-subject narrative handling, natural-history-comparator framing, and designation-aware introduction sections.
Learn more →PSUR / PBRER / DSUR
Safety reporting that maintains consistency across long post-approval periods, carrying forward unchanged context and flagging new findings clearly.
Learn more →CMC (eCTD Module 3)
Module 3 for biologics, gene therapies, and advanced therapy medicinal products common in rare disease — with consolidation across specialised manufacturing documentation.
Learn more →Regulatory context we keep in mind
Not a substitute for your regulatory strategy — just the background Asthra is aware of
FDA Orphan Drug Act and Rare Diseases guidance
Frames the designation lifecycle, single-arm trial acceptability, and post-marketing commitment expectations for orphan-designated programs.
21st Century Cures Act and accelerated approval pathways
Shapes the evidence bar for initial approval and the commitment structure for confirmatory post-approval studies.
EMA PRIME scheme
Equivalent accelerated pathway in the EU, with its own briefing-document conventions. Asthra's templates are configurable to match.
ICH E17 — multi-regional clinical trials
Relevant when a rare-disease trial recruits across multiple regulatory regions, which is common given the population size.
Rare-disease programs carry more regulatory writing per subject enrolled than any other part of the industry. Asthra reduces the time spent on the mechanical half of that load. The clinical judgement, the per-subject nuance, the designation strategy — those stay with the team that understands the disease.
See Asthra on a rare disease document
Bring a real source file — protocol, PSUR, CER, or Module 3 — and we'll run Asthra against it in a live demo.
Last updated: 16 April 2026